Dataset Information

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease.

ABSTRACT: Chronic granulomatous disease (CGD) is a primary immunodeficiency disease caused by impaired phagocytic function. Hematopoietic stem cell transplantation (HSCT) is a definitive cure for CGD; however, the use of HSCT is limited because of associated problems, including transplantation-related mortality and engraftment failure. We report a case of a patient with CGD who underwent successful HSCT following a targeted busulfan and fludarabine reduced-toxicity myeloablative conditioning. Intravenous busulfan was administered once daily for 4 consecutive days (days -8 to -5), and the target area under the curve was 75,000 µg·hr/L. Fludarabine (40 mg/m2) was administered once daily for 6 consecutive days from days -8 to -3. Antithymocyte globulin (2.5 mg/kg/day) was administered from days -4 to -2. The patient underwent successful engraftment and did not have any severe toxicity related to the transplantation. Conditioning with a targeted busulfan and fludarabine regimen could provide a better outcome for HSCT in CGD, with close regulation of the busulfan dose.

SUBMITTER: Ju HY

PROVIDER: S-EPMC5177714 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease.

Ju Hee Young HY Kang Hyoung Jin HJ Hong Che Ry CR Lee Ji Won JW Kim Hyery H Song Sang Hoon SH Yu Kyung-Sang KS Jang In-Jin IJ Park June Dong JD Park Kyung Duk KD Shin Hee Young HY Kim Joong-Gon JG Ahn Hyo Seop HS

Korean journal of pediatrics 20161130 Suppl 1

Chronic granulomatous disease (CGD) is a primary immunodeficiency disease caused by impaired phagocytic function. Hematopoietic stem cell transplantation (HSCT) is a definitive cure for CGD; however, the use of HSCT is limited because of associated problems, including transplantation-related mortality and engraftment failure. We report a case of a patient with CGD who underwent successful HSCT following a targeted busulfan and fludarabine reduced-toxicity myeloablative conditioning. Intravenous ...[more]

PMID: 28018447

Similar Datasets

Project description:Large, multicenter studies comparing commonly used reduced-intensity conditioning (RIC) approaches in follicular lymphoma (FL) have not been performed. Using the Center for International Blood and Marrow Transplant Research database, we report the outcomes of the 2 most commonly used RIC approaches, fludarabine and busulfan (Flu/Bu) versus fludarabine, cyclophosphamide, and rituximab (FCR) in FL patients. We evaluated 200 FL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received RIC with either Flu/Bu (n?=?98) or FCR (n?=?102) during 2008 to 2014. All patients received peripheral blood grafts, and graft-versus-host disease (GVHD) prophylaxis was limited to calcineurin inhibitor-based approaches. Median follow-up of survivors in the Flu/Bu and FCR groups was 48 months and 46 months, respectively. On univariate analysis in the Flu/Bu and FCR groups, the 3-year rates of nonrelapse mortality (11% versus 11%, P?=?.94), relapse/progression (18% versus 15%, P?=?.54), progression-free survival (PFS) (71% versus 74%, P?=?.65), and overall survival (OS) (73% versus 81%, P?=?.18) were not significantly different. On multivariate analysis no difference was seen between the FCR and Flu/Bu cohorts in terms of grades II to IV (relative risk [RR],?1.06; 95% confidence interval [CI],?.59 to 1.93; P?=?.84) or grades III to IV (RR,?1.18; 95% CI, .47 to 2.99; P?=?.72) acute GVHD, nonrelapse mortality (RR,?.83; 95% CI, .38 to 1.82; P?=?.64), relapse/progression (RR,?.99; 95% CI, .49 to 1.98; P?=?.97), PFS (RR,?.92; 95% CI, .55 to 1.54; P?=?.76), or OS (RR,?.70; 95% CI, .40 to 1.23; P?=?.21) risk. However, RIC with FCR was associated with a significantly reduced chronic GVHD risk (RR,?.52; 95% CI, .36 to .77; P?=?.001). RIC with either Flu/Bu or FCR in patients with FL undergoing allo-HCT provides excellent 3-year OS, with acceptable rates of nonrelapse mortality. FCR-based conditioning was associated with a lower risk of chronic GVHD.

Dataset Information

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease.

Publications

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure